alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 41 (Wednesday, March 3, 2010)]
[Notices]
[Pages 9606-9607]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4040]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections

[[Page 9607]]

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant 
applications and the discussions could disclose confidential trade 
secrets or commercial property such as patentable material, and 
personal information concerning individuals associated with the grant 
applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel NIDA-K Conflicts.
    Date: March 8, 2010.
    Time: 5 p.m. to 7 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Kristen V. Huntley, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, 
Bethesda, MD 20892-8401. 301-435-1433. <a href="/cdn-cgi/l/email-protection#cca4b9a2b8a0a9b5a78ca1ada5a0e2a2a5a4e2aba3ba"><span class="__cf_email__" data-cfemail="dfb7aab1abb3baa6b49fb2beb6b3f1b1b6b7f1b8b0a9">[email protected]</span></a>.
    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel NIDA CEBRA R21 Review.
    Date: March 17, 2010.
    Time: 9 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6101 Executive Boulevard, 
Rockville, MD 20852. (Virtual Meeting.)
    Contact Person: Gerald L. McLaughlin, PhD, Scientific Review 
Administrator, Office of Extramural Affairs, National Institute on 
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., 
Bethesda, MD 20892-8401. 301-402-6626. <a href="/cdn-cgi/l/email-protection#6f08025e5b5a0e2f01060741080019"><span class="__cf_email__" data-cfemail="dcbbb1ede8e9bd9cb2b5b4f2bbb3aa">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: February 19, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4040 Filed 3-2-10; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 74.2261 D&C Orange No. 11. ( a ) *Identity and specifications.* The color additive D&C Orange No. 11 shall conform in identity and specifications to the requirements of § 74.1261(a)(1) and (b).
( b ) *Uses and restrictions.* D&C Orange No. 11 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( c ) *Labeling requirements.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Orange No. 11 shall be certified in accordance with regulations in part 80 of this chapter.
[46 FR 18954, Mar. 27, 1981]
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of Central Wireless,  Inc. (the
"Company")  on Form 10-QSB for the period  ended June 30, 2003 as filed with the
Securities and Exchange  Commission on the date hereof (the  "Report"),  each of
the  undersigned,  in the capacities and on the dates  indicated  below,  hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to his knowledge:

         1. The Report fully complies with the  requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         2. The  information  contained in the Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of  operation of the
Company.

Date: March 19, 2004            By: /s/ Kenneth W. Brand
                                    -------------------------------------------
                                Name: Kenneth W. Brand
                                Title: Chief Executive Officer and Acting
                                       Principal Accounting Officer


         A signed original of this written statement required by Section 906, or
other  document  authentications,   acknowledging,  or  otherwise  adopting  the
signature  that  appears in typed form  within  the  electronic  version of this
written  statement  required  by  Section  906,  has been  provided  to  Central
Wireless,  Inc. and will be retained by Central Wireless,  Inc. and furnished to
the Securities and Exchange Commission or its staff upon request.
§ 507.77 Timeframe for issuing a decision on an appeal. ( a ) If you appeal the order without requesting a hearing, the presiding officer must issue a written report that includes a final decision confirming or revoking the withdrawal by the 10th calendar day after the appeal is filed.
( b ) If you appeal the order and request an informal hearing: ( 1 ) If FDA grants the request for a hearing and the hearing is held, the presiding officer must provide a 2 calendar day opportunity for the hearing participants to review and submit comments on the report of the hearing under § 507.73(c)(4), and must issue a final decision within 10 calendar days after the hearing is held; or
( 2 ) If FDA denies the request for a hearing, the presiding officer must issue a final decision on the appeal confirming or revoking the withdrawal within 10 calendar days after the date the appeal is filed.
mcf_Exhibit_104



		

			Exhibit 10.4

		





		
			CONTANGO OIL & GAS COMPANY
		

		
			 
		

		
			Director Compensation Plan
		

		
			 
		

		
			(Effective 5/11/17)
		

		
			 
		

		
			Cash Compensation
		

			
	
			
				 ·
			

			
	
			
			Annual Retainer Fees (all payable quarterly, in arrears, with appropriate adjustments for partial periods)




			
	
			
				 o
			

			
	
			
			Board membership - $50,000 per year




			
	
			
				 o
			

			
	
			
			Non-Executive Board Chairman - $50,000 per year




			
	
			
				 o
			

			
	
			
			Audit Committee Chairman - $15,000 per year




			
	
			
				 o
			

			
	
			
			Compensation Committee Chairman - $10,000 per year




			
	
			
				 o
			

			
	
			
			Nominating & Governance Committee Chairman - $9,500 per year




			
	
			
				 o
			

			
	
			
			No separate retainer fee for Investment Committee Chairman




		
			 
		

			
	
			
				 ·
			

			
	
			
			Meeting Fees (all payable quarterly, in arrears)




			
	
			
				 o
			

			
	
			
			Regular Board 




			
	
			
				 §
			

			
	
			
			$1,000 per meeting attended (whether in person or telephonic)




			
	
			
				 §
			

			
	
			
			No maximum per year




			
	
			
				 o
			

			
	
			
			Committee Meetings




			
	
			
				 §
			

			
	
			
			$1,000 per meeting attended (whether in person or telephonic)




			
	
			
				 §
			

			
	
			
			No maximum per year




			
	
			
				 §
			

			
	
			
			Payable in addition to regular board meetings, even if on same day




		
			 
		

		
			Equity Compensation
		

			
	
			
				 ·
			

			
	
			
			Annual grants (with appropriate adjustments for partial periods)




			
	
			
				 o
			

			
	
			
			$110,000 in Restricted Stock, vesting on the first anniversary of the date of grant




			
	
			
				 o
			

			
	
			
			Pro-rated amount granted upon initial election for new members




			
	
			
				 o
			

			
	
			
			All pro-rated grants based on portion of service year remaining between date of grant and the next May 31st




		
			 
		

		
			Other
		

			
	
			
				 ·
			

			
	
			
			Each Director is required to maintain ownership of at least fifty percent (50%) of the equity granted within the last three calendar years for service on the Board.  The Compensation Committee is expected to confirm compliance annually.  




		
			 
		

			
	
			
				 ·
			

			
	
			
			Payment of reasonable travel expenses associated with Board and Committee Meeting attendance.




		
			 
		

			
	
			
				 ·
			

			
	
			
			No Director who is an employee of the Company will be compensated for service as a member of the Board of Directors or any committee of the Board of Directors.
# C_2017129EN.01001501.xml

| 24.4.2017 | EN | Official Journal of the European Union | C 129/15 |
| --- | --- | --- | --- |

24.4.2017

EN

Official Journal of the European Union

C 129/15

---

Judgment of the General Court of 7 March 2017 — Lauritzen Holding v EUIPO — DK Company (IWEAR)

(Case T-622/14) (1)

1

((European Union trade mark - Opposition proceedings - Application for European Union word mark IWEAR - Earlier European Union word mark INWEAR - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2017/C 129/24)

Language of the case: English

Parties

Parties

Applicant: Lauritzen Holding AS (Drøbak, Norway) (represented by: P. Walsh and S. Dunstan, Solicitors)

Applicant:

Defendant: European Union Intellectual Property Office (represented initially by P. Bullock and subsequently by D. Hanf, acting as Agents)

Defendant:

Intervener: DK Company A/S (Ikast, Denmark) authorised to replace the other party to the proceedings before the Board of Appeal of EUIPO (represented initially by M. Nielsen and E. Skovbo, and subsequently by E. Skovbo, lawyers)

Intervener:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 2 June 2014 (Case R 1935/2013-2), concerning opposition proceedings between IC Companys A/S and Lauritzen Holding.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Lauritzen Holding AS to pay the costs, including the costs necessarily incurred by IC Companys A/S for the purposes of the proceedings before the Board of Appeal of the European Union Intellectual Property Office (EUIPO). |
| --- | --- |

2.

Orders Lauritzen Holding AS to pay the costs, including the costs necessarily incurred by IC Companys A/S for the purposes of the proceedings before the Board of Appeal of the European Union Intellectual Property Office (EUIPO).

---

(1)  OJ C 351, 6.10.2014.

1

---
#### § 801.4 Meaning of intended uses.

###### Cross Reference

Link to an amendment published at 82 FR 2217, Jan. 9, 2017.

###### Cross Reference

This amendment was delayed until Mar. 21, 2017, at 82 FR 9501, Feb. 7, 2017.

###### Cross Reference

This amendment was further delayed until Mar. 19, 2018, at 82 FR 14319, Mar. 20, 2017.

###### Cross Reference

This amendment delayed indefinitely at 83 FR 11639, Mar. 16, 2018.

The words *intended uses* or words of similar import in §§ 801.5, 801.119, 801.122, and 1100.5 of this chapter refer to the objective intent of the persons legally responsible for the labeling of an article (or their representatives). The intent may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. Objective intent may be shown, for example, by circumstances in which the article is, with the knowledge of such persons or their representatives, offered or used for a purpose for which it is neither labeled nor advertised; provided, however, that a firm would not be regarded as intending an unapproved new use for a device approved, cleared, granted marketing authorization, or exempted from premarket notification based solely on that firm's knowledge that such device was being prescribed or used by health care providers for such use. The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he or she received the article, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses.

[86 FR 41401, Aug. 2, 2021]
C OURT OF A PPEALS FOR THE

F IRST D ISTRICT OF T EXAS AT H OUSTON

O RDER

Appellate case name: Jusden A. Kukowski, Jesse David Hartung d/b/a H & H Hauling, Inc

and H & H Hauling, Inc. v. Bryce G. Burton

Appellate case number: 01

- 14

- 00129

- CV

Trial court case number: 13CV1174

Trial court: 56th District Court of Galveston County

The Court requests a response from a ppellee, Bryce Burton, to the Motion for Stay of

Trial Court Proceedings filed by appellants on March 1, 2014. The response, if any, is due by

noo n on Friday, April 11, 2014.

It is so ORDERED.

Judge’s signature: /s/ Harvey Brown

X Act ing individually  Acting for the Court

Date: April 3, 2014
<PAGE>   1

                                                                    EXHIBIT 23.1





               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS



         We consent to the reference to our firm under the caption "Experts" in
Amendment No. 2 to the Registration Statement (Form S-3 No. 333-72261) and
related Prospectus of NeoPath, Inc. for the registration of 2,900,000 shares of
its common stock and to the incorporation by reference therein of our report
dated February 9, 1999, with respect to the financial statements of NeoPath,
Inc. incorporated by reference in its Annual Report (Form 10-K) for the year
ended December 31, 1998, filed with the Securities and Exchange Commission.





                                         ERNST & YOUNG LLP


Seattle, Washington

July 1, 1999
**Exhibit 31.1****CERTIFICATIONS**I, Richard E. Gaetz, certify that:1.      I have reviewed this Annual Report on Form 10-K/A of Vitran Corporation Inc.;2.      Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to the periodcovered by this report;3.      Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, the periodspresented in this report;4.      The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange ActRules 13a-15(f) and 15d-15(f)) for the registrant and have:a)      Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that material informationrelating to the registrant, including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this report is being prepared;b)      Designed such internal control over financial reporting, or caused such internal control overfinancial reporting to be designed under our supervision, to provide reasonable assurance regardingthe reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with generally accepted accounting principles;c)      Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presentedin this report our conclusions about the effectiveness of the disclosure controls and procedures,as of the end of the period covered by this report based on such evaluation; andd)      Disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal control overfinancial reporting; and5.      The registrant’s other certifying officer and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to the registrant’s auditorsand the Audit Committee of the registrant’s Board of Directors:a)      All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financial information; andb)      Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control over financial reporting.Date:  February 15, 2008           /s/  RICHARD E. GAETZ    Richard E. Gaetz    President and
EXHIBIT
32.1
 
 CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER
 
 Pursuant
to Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C. 1350)
and
 Rules
13a-14(b) of the Securities Exchange Act of 1934
 
 I, Daniel
A. Ninivaggi, President of Icahn Enterprises G.P. Inc., the
general partner of Icahn Enterprises L.P. (the “Registrant”), certify that, to
the best of my knowledge, based upon a review of the Icahn Enterprises L.P.
quarterly report on Form 10-Q for the period ended June 30, 2010 of the
Registrant (the “Report”):
  (1) The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and
  (2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Registrant.
  /s/  Daniel
      A. NinivaggiDaniel
      A. NinivaggiPresident
 of Icahn Enterprises G.P.
      Inc., the general partner of Icahn Enterprises L.P.
 
 Date:
August 4, 2010
Exhibit 3-5

                              CERTIFICATE OF TRUST
                                       OF
                              PSEG FUNDING TRUST IV

      THIS CERTIFICATE OF TRUST of PSEG Funding Trust IV (the "Trust"), dated as
of July 31,  2002,  is being  duly  executed  and filed by the  undersigned,  as
trustees,  to form a business  trust under the Delaware  Business  Trust Act (12
Del. C.ss.3801, et seq.) (the "Act").

            (i) Name. The name of the business trust being formed hereby is PSEG
Funding Trust IV.

            (ii) Delaware Trustee.  The name and business address of the trustee
of the Trust in the State of  Delaware  are  Wachovia  Trust  Company,  National
Association, One Rodney Square, 920 King Street, Suite 102, Wilmington DE 19801.

            (iii) Counterparts. This Certificate of Trust may be executed in one
or more  counterparts,  all of which together shall  constitute one and the same
instrument.

            (iv) Effective Date. This Certificate of Trust shall be effective as
of its filing with the Secretary of State of the State of Delaware.

      IN WITNESS WHEREOF, the undersigned, being the trustees of the Trust, have
executed  this  Certificate  of Trust  as of the date  first  above  written  in
accordance with Section 3811(a) of the Act.

                                         WACHOVIA TRUST COMPANY, NATIONAL
                                         ASSOCIATION, as Trustee

                                         By: /s/ AMY L. MARTIN
                                             -----------------------------------
                                            Name:  Amy L. Martin
                                            Title: Assistant Vice President

                                         MORTON A. PLAWNER, as Trustee

                                         /s/ MORTON A. PLAWNER
                                         ---------------------------------------
                                         Morton A. Plawner
I 

118TH CONGRESS 

1ST SESSION H. R. 759 

To limit the authority of the Secretary of the Treasury to authorize United 

States financial institutions to engage in certain Russian-related energy 

transactions. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 2, 2023 

Mr. BARR introduced the following bill; which was referred to the Committee 

on Financial Services 

A BILL 

To limit the authority of the Secretary of the Treasury 

to authorize United States financial institutions to engage in certain Russian-related energy transactions. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘No Energy Revenues 

5 for Russian Hostilities Act of 2023’’. 

6 SEC. 2. LIMITATION ON AUTHORIZING CERTAIN RUSSIAN7 RELATED ENERGY TRANSACTIONS. 

8 (a) IN GENERAL.—The Secretary of the Treasury 

9 may not authorize, or continue in effect any existing auVerDate Sep 11 2014 20:43 Feb 23, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H759.IH H759

pbinns on DSKJLVW7X2PROD with $$_JOB
2 

•HR 759 IH

1 thorization for, a United States financial institution to en2 gage in a transaction described under General License No. 

3 8E, dated December 15, 2022, with respect to Executive 

4 Order 14024 of April 15, 2021. 

5 (b) WAIVER.—The Secretary may waive subsection 

6 (a) for up to 90 days at a time for a United States finan7 cial institution upon certifying to the Committee on Fi8 nancial Services of the House of Representatives and the 

9 Committee on Banking, Housing, and Urban Affairs of 

10 the Senate that— 

11 (1) the waiver is only applicable to transactions 

12 that involve funds owed to a Russian person; and 

13 (2) the funds, subject to approval by the Sec14 retary, are to be used for the sale of agricultural 

15 commodities, food, medicine, or medical devices. 

16 (c) TERMINATION.—Subsection (a) shall have no 

17 force or effect on the earlier of— 

18 (1) the date that is 5 years after the date of en19 actment of this Act; or 

20 (2) 30 days after the date that the President 

21 reports to Congress that the Government of the Rus22 sian Federation has ceased its destabilizing activities 

23 with respect to the sovereignty and territorial integ24 rity of Ukraine. 

Æ 


pbinns on DSKJLVW7X2PROD with $$_JOB